


CS DIAGNOSTIC CORP. CSDX
SUPPLEMENTAL FILING

DECEMBER 6, 2024




Supplemental Filing Disclosure

CS DIAGNOSTICS CORP. CSDX
A Wyoming Corporation
Stresemannallee 4c
Neuss, Germany 41460
Telephone +49 (0)2131-151 08
<http://www.csdcorp.us>

AMEND AND RESTATEMENT OF THE CERTIFICATE OF DESIGNATION
OF THE PREFERRED SERIES B SHARES

On December 6, 2024, the Board of Directors and the majority shareholders have approved to Amend and Restate the Certificate of Designation of the Preferred Series B Shares to include a Limitation on the Beneficial Owner Share so the Conversion of the Preferred Shares into Common Stock for a Beneficial Owner will not exceed 9.9% of the Total Outstanding Shares at the time of the Conversion. The Issuer will amend the Articles of Incorporation with the Secretary of State for the Wyoming.



Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).


The certifications shall follow the format below:

I, Thomas Fahrhoefer, certify that:

1. I have reviewed this Supplemental Filing Disclosure dated December 6, 2024
of CS Diagnostic Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 6, 2024

/s/ Thomas Fahrhoefer



Principal Financial Officer:

I, Mohammad EsSayed , certify that:

1. I have reviewed this Supplemental Filing Disclosure dated December 6, 2024 of CS Diagnostic Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

December 6, 2024

/s/ Mohammad EsSayed



**A SPECIAL MEETING OF THE BOARD OF DIRECTORS OF CS DIAGNOSTICS CORP.,
was held on December 6, 2024.**

A quorum was called and the Directors, Thomas Fahrhoefer, Thomas Migotsch, and Mohammad EsSayed were present and a quorum was present. The meeting was held telephonically due to the location of the Directors.

The Chief Financial Officer, Mohammad EsSayed, reported to the Board of Directors the desire to Amend the Certificate of Designation of the Preferred Series B shares to ensure no shareholder could violate SEC guidelines and convert more than 9.9% of the total outstanding common stock.

WHEREAS the President recommended that it is in the best interest of the shareholders of the Company that it mends the Articles of Incorporation with an Amendment and Restatement Certificate of Designation of Preferred Series B.

RESOLVED, Pursuant to Wyoming Revised Statues Title 17, Chapter 10, Article 10, Sections 17-16-602 and section-17-19-1006, that it amends the Articles of Incorporation with an Amendment and Restatement Certificate of Designation of Preferred Series B, as attached hereto as Exhibit C, is approved.


RESOLVED, the Chief Financial Officer, Mohammad EsSayed, is approved to make all requisite filings with the Wyoming Secretary of State and a Supplemental Disclosure of these actions with OTC Markets and the Company Transfer Agent, Transfer Online, Inc., and any other requirements it deems necessary.

I Mohammad EsSayed, the Chief Financial Officer of the Company, do hereby and herein attest the foregoing is a true and correct copy of the Special Meeting of the Board of Directors of CS Diagnostics Corp held on 6th of December 2024.

A handwritten signature in blue ink, appearing to read 'Mohammad EsSayed'.

Mohammad EsSayed
Chief Financial Officer

MAJORITY SHAREHOLDER CONSENT

A handwritten signature in blue ink, appearing to read 'Thomas Fahrhoefer'.

Thomas Fahrhoefer Voting Control Shareholder



AMENDMENT TO THE ARTICLES OF INCORPORATION

ARTICLE IV

AMENDED & RESTATED

CERTIFICATE OF DESIGNATION of SERIES B PREFERRED STOCK of CS DIAGNOSTICS CORP.

The undersigned, Mohammad EsSayed , hereby certifies that: he is the duly elected and active Chief Financial Officer of CS DIAGNOSTICS CORP., a Wyoming corporation (the “Corporation”).

Pursuant to authority given by the Corporation’s Articles of Incorporation in accordance with the requirements of the Corporations Article of the Wyoming Revised Statutes the Board of Directors of the Corporation has duly Reinstated and Ratifies the previous Certificate of Designations for its Preferred Series B Shares. On 18th October 2010, the Corporation amended its Articles of Incorporation and filed the original Certificate of Designation for a Preferred Series “B” Stock. March 31, 2015, the Corporation amended its Articles of Incorporation and filed an Amended Certificate of Designation for its Preferred Series “B” Stock. On March 24, 2024, the Board of Directors approved an Amendment to the Articles of Incorporation and this Restated and Amended Certificate of Designation of Series B Preferred Stock. On December 5, 2024, the Board of Directors approved this Restated and Amended Certification of Designation of Series B Preferred Stock.



This Amended and Restatement of the Certificate of Designation of Series B Preferred Stock shall be applied retroactive to the Amended Certificate of Designation dated March 24, 2024.

SERIES B PREFERRED STOCK

On the 18th of October 2010, the Board of Directors approved and filed a Certificate of Designation for Series B Preferred Shares and as amended on 31 March 2015. The Board does hereby Amend and Restate the Certificate of Designation for Series B Preferred Share the following:

1. **DESIGNATION AND NUMBER OF SHARES.** 20,000,000 shares of Series B Preferred Stock, par value \$.0001 per share (the "Preferred B Stock"), are authorized pursuant to Article IV of the Corporation's Amended Articles of Incorporation (the "Series B Preferred Stock" or "Series B Preferred Shares").
2. **DIVIDENDS.** The holders of Preferred B Stock shall be entitled to receive dividends when, as if declared by the Board of Directors, in its sole discretion.
3. **LIQUIDATION RIGHTS.** Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any stock ranking junior to the Preferred B Stock, the holders of the Preferred B Stock shall be entitled to be paid out of the assets of the Corporation an amount equal to \$1.00 per share or, in the event of an aggregate subscription by any single subscriber for Preferred B Stock in excess of \$100,000, \$.997 per shares, (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares)(the "Preference Value"), plus all declared but unpaid dividends, for each share of Preferred B Stock held by them. After the payment of the full applicable Preference Value of each share of the Preferred B Stock as set forth herein, the remaining assets of the Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Corporation's Common Stock.



4. **CONVERSION.** The Conversion rate of one share Preferred Series B shall be 1 share of Preferred Series B shall be converted into 20,000 shares of common stock of the Corporation. The Corporation agrees upon the submission of a Notice of Conversion to authorize the Secretary of the Corporation to issue a Board Resolution authorizing the conversion and to notify the transfer agent to process the Conversion. The Preferred Series B shareholder is responsible for any legal or transfer agent fees for such conversion. The Conversion of the Preferred Series B shares shall be subject to the following Limitation on Conversion Rights. **Ownership Limitation.** Notwithstanding anything to the contrary in this Certificate of Designation, no shares of Common Stock will be issued or delivered upon any proposed conversion of any Series B Convertible Preferred Stock of any Holder thereof, and no Series B Convertible Preferred Stock of any Holder thereof will be convertible, in each case to the extent, and only to the extent, that such issuance, delivery, conversion or convertibility would cause such Holder to become, directly or indirectly, a Beneficial Owner of a number of shares of Common Stock in excess of the 9.9 % of the Total Outstanding shares of Common Stock . For these purposes, beneficial ownership and calculations of percentage ownership will be determined in accordance with Rule 13d-3 under the Exchange Act. A Person shall be deemed the “Beneficial Owner” of and shall be deemed to beneficially own any shares Common Stock that such Person or any of such person’s affiliates (as defined in Rule 12b-2 under the Exchange Act) or associates (as defined in Rule 12b-2 under the Exchange Act) is deemed to beneficially own, together with any Common Stock beneficially owned by any other persons whose beneficial ownership would be aggregated with such Person for purposes of Section 13(d) of the Exchange Act. Subject to the following proviso, beneficial ownership shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder as in effect on the date hereof; provided that the number of shares of Common Stock beneficially owned by such Person and its Affiliates and associates and any other persons whose beneficial ownership would be aggregated with such Person for purposes of Section 13(d) of the Exchange Act shall include the number of shares of Common Stock issuable upon exercise or conversion of any of the Corporation’s securities or rights to acquire the Common Stock, whether or not such securities or rights are currently exercisable or convertible or are exercisable or convertible only after the passage of time (including the number of shares of Common Stock issuable upon conversion of the Series B Convertible



Preferred Stock in respect of which the beneficial ownership determination is being made), but shall exclude the number of shares of Common Stock that would be issuable upon (A) conversion of the remaining, unconverted portion of any Series B Convertible Preferred Stock beneficially owned by such Person or any of its Affiliates or associates and any other persons whose beneficial ownership would be aggregated with such Person for purposes of Section 13(d) of the Exchange Act and (B) exercise or conversion of the unexercised or unconverted portion of any of the Corporation's other securities subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by such Person or any of its Affiliates or associates and any other persons whose beneficial ownership would be aggregated with such Person for purposes of Section 13(d) of the Exchange Act.

5. **VOTING.** The Preferred Series B shareholders shall have the same voting rights as the Corporations Common Stock Shareholders, e.g. 1 vote for each share of Preferred Series B or Common Stock.

6. **PRICE.** The Board of Directors shall determine the price of issuance of any Preferred Series B Stock.

7. **NOTICES OF RECORD DATE.** Upon (i) any taking by the Corporation of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any distribution, or (ii) any acquisition or other capital reorganization of the Corporation, any reclassification or recapitalization of the capital stock of the Corporation, any merger or consolidation of the Corporation with or into any other corporation, any asset transfer, or any voluntary or involuntary dissolution, liquidation or winding up of the Corporation, the Corporation shall mail to each holder of Series A Preferred Stock at least ten (10) days prior to the record date specified therein a notice specifying: (A) the date on which any such record is to be taken for the purpose of such distribution and a description of such distribution; (B) the date on which any such acquisition, reorganization, reclassification, transfer, consolidation, merger, asset transfer, dissolution, liquidation or winding up is expected to become effective; and (C) the date, if any, that is to be fixed as to when the holders of record of Common Stock (or other securities) shall be entitled



to exchange their shares of Common Stock (or other securities) for securities or other property deliverable upon such acquisition, reorganization, reclassification, transfer, consolidation, merger, asset transfer, dissolution, liquidation or winding up.

IN WITNESS WHEREOF, the undersigned being a duly authorized officer of the Corporation, does file this Certificate of Designation, Rights and Preferences, hereby declaring and certifying that the facts stated herein are true and accordingly has hereunto set his had this 5th day of December, 2024

CS Diagnostics Corp.

A handwritten signature in black ink, appearing to read 'Mohammad EsSayed'.

/s/ Mohammad EsSayed
Mohammad EsSayed
Chief Financial Officer